In fact, parental SW48 and LIM1215 cancer cells were significantly sensitive to cetuximab, panitumumab, SYM004 and MM-151 antibodies inducing growth inhibition, as expected being “quadruple wild type” for KRAS, BRAF, NRAS and PIK3CA genes. This evidence concerns the gene KRAS and cancer.